EDITORIAL
Published on 18 Dec 2024
Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, Volume II
doi 10.3389/fphar.2024.1519858
- 152 views
- Frontiers in Pharmacology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Discovery of Small Molecule Lead Compounds: a Driving Force to Unravel New Anti-Cancer Targets and Mechanisms - Volume II
Discovery of Small Molecule Lead Compounds: a Driving Force to Unravel New Anti-Cancer Targets and Mechanisms - Volume II
11k
Total downloads
22k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 27 Aug 2024
Identification of novel PHGDH inhibitors based on computational investigation: an all-in-one combination strategy to develop potential anti-cancer candidates
doi 10.3389/fphar.2024.1405350
- 753 views
ORIGINAL RESEARCH
Published on 12 Aug 2024
Systematic bioinformatics analysis reveals the role of shikonin in blocking colon cancer progression by identifying senescence-induced genes
doi 10.3389/fphar.2024.1360587
- 719 views
ORIGINAL RESEARCH
Published on 30 Apr 2024
In silico evaluation of anti-colorectal cancer inhibitors by Resveratrol derivatives targeting Armadillo repeats domain of APC: molecular docking and molecular dynamics simulation
doi 10.3389/fonc.2024.1360745
- 1,719 views
- 1 citation
ORIGINAL RESEARCH
Published on 11 Mar 2024
Targeting hexokinase 2 for oral cancer therapy: structure-based design and validation of lead compounds
doi 10.3389/fphar.2024.1346270
- 2,005 views
REVIEW
Published on 08 Mar 2024
Natural products reverse cancer multidrug resistance
doi 10.3389/fphar.2024.1348076
- 2,684 views
- 2 citations
ORIGINAL RESEARCH
Published on 06 Mar 2024
Epigenetic small-molecule screen for inhibition and reversal of acinar ductal metaplasia in mouse pancreatic organoids
doi 10.3389/fphar.2024.1335246
- 1,550 views
- 5 citations
ORIGINAL RESEARCH
Published on 30 Nov 2023
Design, synthesis, and evaluation of 4-(3-(3,5-dimethylisoxazol-4-yl)benzyl)phthalazin-1(2H)-one derivatives: potent BRD4 inhibitors with anti-breast cancer activity
doi 10.3389/fphar.2023.1289003
- 1,148 views
- 3 citations
Published in
Frontiers in Pharmacology
- Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Impact
- 22kTopic views
- 9,456Article views
- 11kArticle downloads